Page last updated: 2024-11-05

buclizine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Buclizine is an antihistamine that is used to treat nausea and vomiting. It is also used to prevent motion sickness. Buclizine is a central nervous system depressant. It works by blocking the action of histamine, a chemical that is released in the body during allergic reactions. Buclizine is available as a tablet and a syrup. It is typically taken by mouth. Buclizine can cause drowsiness, dizziness, and dry mouth. It can also interact with other medications, so it is important to talk to your doctor before taking buclizine. Buclizine has been studied for its potential to treat other conditions, such as anxiety and Parkinson's disease. However, it is not approved for these uses.'

luteolinidin: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

buclizine : An N-alkylpiperazine carrying (4-chlorophenyl)(phenyl)methyl and 4-tert-butylbenzyl groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

1-octyl-3-methylimidazolium: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3-methyl-1-octylimidazolium : A 1-alkyl-3-methylimidazolium in which the alkyl substituent at C-1 is octyl. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID441701
CHEMBL ID1275834
CHEBI ID6584
SCHEMBL ID676808
MeSH IDM0135650
PubMed CID6729
CHEMBL ID1201271
CHEBI ID3205
SCHEMBL ID27855
MeSH IDM0135650
PubMed CID2734224
CHEMBL ID1198008
CHEBI ID61341
SCHEMBL ID34812
MeSH IDM0135650

Synonyms (117)

Synonym
NCI60_033512
2-(3,4-dihydroxyphenyl)chromenylium-5,7-diol
2-(3,4-dihydroxy-phenyl)-5,7-dihydroxy-chromenylium
nsc693578
CHEBI:6584 ,
2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromenylium
C08652
luteolinidin
CHEMBL1275834
bdbm50347144
SCHEMBL676808
luteolinidin cation
unii-935os7whp6
luteolinidin ion
935os7whp6 ,
16975-93-2
1-benzopyrylium, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-1$l^{4}-chromen-1-ylium
luteolidin
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-1-benzopyrylium(1+), 9ci
5,7,3',4'-tetrahydroxyflavylium
Q3062931
AC-15954
1-(4-tert-butylbenzyl)-4-[(4-chlorophenyl)(phenyl)methyl]piperazine
CHEBI:3205 ,
buclizina
buclizinum
piperazine, 1-[(4-chlorophenyl)phenylmethyl]-4-[[4-(1,1-dimethylethyl)phenyl]methyl]-
NCI60_002006
1-[(4-chlorophenyl)(phenyl)methyl]-4-{[4-(1,1-dimethylethyl)phenyl]methyl}piperazine
1-(4-tert-butylbenzyl)-4-((4-chlorophenyl)(phenyl)methyl)piperazine
buclina (tn)
buclizine (inn)
D07547
buclizina [inn-spanish]
piperazine, 1-(p-tert-butylbenzyl)-4-(p-chloro-alpha-phenylbenzyl)-
buclizinum [inn-latin]
buclizine [inn:ban]
buclifen
ah 2526
brn 0349567
histabuticine
piperazine, 1-((4-chlorophenyl)phenylmethyl)-4-((4-(1,1-dimethylethyl)phenyl)methyl)-
aphilan-r base
histabutyzine
histabutizine
einecs 201-448-1
1-[(4-tert-butylphenyl)methyl]-4-[(4-chlorophenyl)-phenyl-methyl]piperazine
82-95-1
buclizine
C07777
DB00354
1-(p-tert-butylbenzyl)-4-(4-chloro-alpha-phenylbenzyl)piperazine
1-[(4-tert-butylphenyl)methyl]-4-[(4-chlorophenyl)-phenylmethyl]piperazine
L000971
CHEMBL1201271
posdel
hitabutyzyne
AKOS015962163
4-23-00-00082 (beilstein handbook reference)
0c94v6x681 ,
unii-0c94v6x681
gtpl7134
1-[(4-tert-butylphenyl)methyl]-4-[(4-chlorophenyl)(phenyl)methyl]piperazine
buclizine [who-dd]
buclizine [vandf]
buclizine [mi]
buclizine [inn]
1-(p-tert-butylbenzyl)-4-(p-chloro-.alpha.-phenylbenzyl)piperazine
SCHEMBL27855
bucladin (salt/mix)
longifene (salt/mix)
ucb-4445 (salt/mix)
MOYGZHXDRJNJEP-UHFFFAOYSA-N
piperazine, 1-(p-tert-butylbenzyl)-4-(p-chloro-.alpha.-phenylbenzyl)-
1-(4-tert-butylbenzyl)-4-[(4-chlorophenyl)(phenyl)methyl]piperazine #
piperazine, 1-((4-chlorophenyl)phenylmethyl)-4-((4-(1,1-dimethylethyl)phenyl)methyl)-, (+)-
UFN4445AF2 ,
163837-51-2
163837-52-3
buclizine, (+)-
1178B2VD9B ,
buclizine, (-)-
piperazine, 1-((4-chlorophenyl)phenylmethyl)-4-((4-(1,1-dimethylethyl)phenyl)methyl)-, (-)-
DTXSID0022694
unii-1178b2vd9b
unii-ufn4445af2
mfcd00242701
NCGC00386387-02
Q4859329
F15132
NCGC00386387-03
1-(4-(tert-butyl)benzyl)-4-((4-chlorophenyl)(phenyl)methyl)piperazine
NCGC00386387-01
BS-49162
CS-0017445
HY-A0128
EN300-7414506
1-methyl-3-octyl-imidazol-3-ium
3-methyl-1-octyl-1h-imidazol-3-ium
CHEBI:61341 ,
3-methyl-1-octylimidazolium
[omim]
1-octyl-3-methylimidazolium
[c8mim]
NCGC00248538-01
NCGC00248538-02
CHEMBL1198008
SCHEMBL34812
1-methyl-3-octylimidazolium
DTXSID8048076
WXMVWUBWIHZLMQ-UHFFFAOYSA-N
Q27131045
STARBLD0022111
1-methyl-3-octyl-1h-imidazol-3-ium
856P4L9QUQ
1-methyl-3-octyl-1h-imidazolium

Research Excerpts

Overview

Buclizine (BCZ) is a chiral synthetic piperazine derivative. It has antihistaminic, anti-muscarinic and antiemetic properties.

ExcerptReferenceRelevance
"Buclizine (BCZ) is a chiral synthetic piperazine derivative which has antihistaminic, anti-muscarinic and antiemetic properties, and has been reintroduced as an appetite stimulant, especially for pediatric patients. "( Buclizine crystal forms: First Structural Determinations, counter-ion stoichiometry, hydration, and physicochemical properties of pharmaceutical relevance.
Bitencourt, M; de Melo, CC; Doriguetto, AC; Freitas, JTJ; Viana, ALM; Viana, OMMS, 2020
)
3.44

Toxicity

ExcerptReferenceRelevance
" However, previous studies have primarily focused on their lethal toxicities, and data were limited on their toxic effects at nonlethal doses."( Oxidative stress and genotoxicity of the ionic liquid 1-octyl-3-methylimidazolium bromide in zebrafish (Danio rerio).
Dong, M; Du, Z; Guo, Y; Liu, T; Wang, J; Xie, H; Zhu, L, 2014
)
0.4

Bioavailability

ExcerptReferenceRelevance
" Bioavailability data for paracetamol derived from the results were similar to those reported by other workers who studied suppositories containing paracetamol as the only active ingredient."( The relative bioavailability of paracetamol after rectal administration of suppositories containing a mixture of paracetamol, codeine phosphate and buclizine hydrochloride in healthy volunteers.
Burgess, HA; Merrington, DM; Oliver, WJ; Rogers, HJ; Thomson, A, 1985
)
0.47
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" This reduction of freely dissolved concentration gave rise to remarkable reduction of bioavailability and toxicity of the two ILs."( Sorption to dissolved humic acid and its impacts on the toxicity of imidazolium based ionic liquids.
Cai, XQ; Jiang, GB; Jiang, WW; Liu, JF; Luo, WR; Zhang, Z, 2011
)
0.37

Dosage Studied

ExcerptRelevanceReference
" The implementation of this assay to the screening of a highly diverse academic chemical library of 14,300 molecules yielded, after secondary assays and generation of dose-response curves, the identification of two natural product inhibitors, cyanidin and delphinidin."( Identification by high-throughput screening of inhibitors of Schistosoma mansoni NAD(+) catabolizing enzyme.
Haiech, J; Hibert, M; Kellenberger, E; Kuhn, I; Lobstein, A; Muller-Steffner, H; Rognan, D; Said-Hassane, F; Schuber, F; Villa, P, 2010
)
0.36
"An isocratic reversed phase high-performance liquid chromatographic (HPLC) method with ultraviolet detection at 230 nm has been developed for the determination of buclizine hydrochloride in human serum and dosage formulation."( Quantitation of buclizine hydrochloride in pharmaceutical formulations and human serum by RP-HPLC.
Arayne, MS; Siddiqui, FA; Sultana, N, 2006
)
0.88
" Thus, the proposed method is suitable for the simultaneous analysis of active ingredients in tablet dosage forms and human serum."( Simultaneous determination of gliquidone, fexofenadine, buclizine, and levocetirizine in dosage formulation and human serum by RP-HPLC.
Arayne, MS; Mirza, AZ; Siddiqui, FA; Sultana, N,
)
0.38
" M8OI activated the human ERĪ± in MCF7 cells in a dose-response manner."( The ionic liquid 1-octyl-3-methylimidazolium (M8OI) is an activator of the human estrogen receptor alpha.
Agius, L; Blain, PG; Hotham, WE; Kass, GEN; Lakey, AF; Leitch, AC; Wright, MC, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
antiemeticA drug used to prevent nausea or vomiting. An antiemetic may act by a wide range of mechanisms: it might affect the medullary control centres (the vomiting centre and the chemoreceptive trigger zone) or affect the peripheral receptors.
cholinergic antagonistAny drug that binds to but does not activate cholinergic receptors, thereby blocking the actions of acetylcholine or cholinergic agonists.
histamine antagonistHistamine antagonists are the drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists.
local anaestheticAny member of a group of drugs that reversibly inhibit the propagation of signals along nerves. Wide variations in potency, stability, toxicity, water-solubility and duration of action determine the route used for administration, e.g. topical, intravenous, epidural or spinal block.
central nervous system depressantA loosely defined group of drugs that tend to reduce the activity of the central nervous system.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
5-hydroxyanthocyanidinAny anthocyanidin cation that carries a hydroxy substituent at position 5.
N-alkylpiperazine
monochlorobenzenesAny member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
1-alkyl-3-methylimidazoliumAn imidazolium ion with an alkyl substituent at the 1-position and a methyl substituent at the 3-position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
luteolinidin 5-O-glucoside biosynthesis416
luteolinidin 5-O-glucoside biosynthesis417
Buclizine H1-Antihistamine Action87

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)IC50 (µMol)6.00006.00006.83338.2000AID603318
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (25)

Processvia Protein(s)Taxonomy
response to hypoxiaADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
signal transductionADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
female pregnancyADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
response to xenobiotic stimulusADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
negative regulation of neuron projection developmentADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
artery smooth muscle contractionADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
NAD metabolic processADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
positive regulation of cell growthADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
positive regulation of B cell proliferationADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
positive regulation of insulin secretionADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
response to estradiolADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
response to retinoic acidADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
response to progesteroneADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
response to hydroperoxideADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
B cell proliferationADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
negative regulation of apoptotic processADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
negative regulation of bone resorptionADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
negative regulation of DNA-templated transcriptionADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
positive regulation of DNA-templated transcriptionADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
positive regulation of vasoconstrictionADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
B cell receptor signaling pathwayADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
long-term synaptic depressionADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
response to interleukin-1ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
apoptotic signaling pathwayADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
NAD+ nucleosidase activityADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
transferase activityADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
identical protein bindingADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
NAD+ nucleotidase, cyclic ADP-ribose generatingADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
phosphorus-oxygen lyase activityADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
plasma membraneADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
cell surfaceADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
membraneADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
basolateral plasma membraneADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
nuclear membraneADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
extracellular exosomeADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
plasma membraneADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID603318Inhibition of human CD38 using 20 uM 1, N6-etheno NAD+ as substrate by continuous fluorimetric method2011Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
Flavonoids as inhibitors of human CD38.
AID537627Inhibition of Schistosoma mansoni recombinant NAD+ glycohydrolase expressed in Pichia pastoris by continuous fluorometric method2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Identification by high-throughput screening of inhibitors of Schistosoma mansoni NAD(+) catabolizing enzyme.
AID603401Competitive inhibition of human CD38 active site using 20 uM NAD+ as substrate2011Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
Flavonoids as inhibitors of human CD38.
AID603400Competitive inhibition of human CD38 active site under saturating levels of substrate NAD+2011Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
Flavonoids as inhibitors of human CD38.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (85)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (12.94)18.7374
1990's1 (1.18)18.2507
2000's5 (5.88)29.6817
2010's60 (70.59)24.3611
2020's8 (9.41)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 55.67

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index55.67 (24.57)
Research Supply Index3.26 (2.92)
Research Growth Index4.93 (4.65)
Search Engine Demand Index125.31 (26.88)
Search Engine Supply Index2.90 (0.95)

This Compound (55.67)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials1 (4.17%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Reviews1 (2.04%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other16 (100.00%)84.16%
Other23 (95.83%)84.16%
Other48 (97.96%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]